Glucotrack, Inc. (GCTK): Nasdaq/NYSE listing notice — Glucotrack receives second Nasdaq delisting notice; plans to appeal by May 18

Glucotrack, Inc.

First notice on May 11: non-compliance with minimum bid price of $1.00.
Second notice on May 15: stockholders' equity below $2.5M; additional delisting basis.
Company intends to request hearing by May 18 to appeal both deficiencies.
No assurance of success; stock (GCTK) faces potential delisting from Nasdaq Capital Market.

item 3.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Glucotrack, Inc. received a nasdaq delisting notice notice regarding stockholders equity (rules 5550(b)(1)).

Exchange: nasdaq
Notice: delisting notice
Deficiency: stockholders equity
Rules: 5550(b)(1)

Exact text from the filing

May 15, 2026, the Company received a second letter from Nasdaq notifying the Company that its Form 10-Q for the period ended March 31, 2026, indicates that the Company no longer meets the $2,500,000 minimum stockholders’

View on SEC.gov

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Glucotrack, Inc. received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: delisting notice
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

May 11, 2026, Glucotrack, Inc. (the “Company”) received a Staff Determination letter (the “Staff Determination”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company

View on SEC.gov

5 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Glucotrack, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-26-023889

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.